Veiledende retningslinjer for diagnostisering og ... - Helse Stavanger

Segmentale dystonier
Generaliserte dystonier
Multifokale dystonier
Hemidystonier
Sekundære dystonier
• Albanese A. Dystonia: clinical approach.
Parkinsonism Relat Disord 2007;13 Suppl
3:S356-61.
• Farbu E, Bindoff LA. [Dopa-responsive dystonia-
-a hereditary dystonia easy to treat]. Tidsskr
Nor Laegeforen 2002;122(4):379-81.
• Geyer HL, Bressman SB. The diagnosis of
dystonia. Lancet Neurol 2006;5(9):780-90.
• Kerty E. [Primary and secondary dystonias].
Tidsskr Nor Laegeforen 2008;128(19):2206-9.
• Klein C, Ozelius LJ. Dystonia: clinical features,
genetics, and treatment. Curr Opin Neurol
2002;15(4):491-7.
• Nygaard TG, Wilhelmsen KC, Risch NJ, et al.
Linkage mapping of dopa-responsive dystoni
(DRD) to chromosome 14q. Nat Genet 1993; 5:
386-91.
• Nygaard TG, Raymond D, Chen C, et al. localisation
of a gene for myoclonus dystonia to chromosome
7q21-31. Ann Neurol 1999; 46: 794-98.
• Segawa M, Hosaka A, Miyagawa F, et al.
Hereditary, progressive dystonia with marked
diurnal fluctuation. Adv Neurol 1976; 14:
215-33.
• Tarsy D, Simon DK. Dystonia. N Engl J Med
2006;355(8):818-29.
Psykososiale aspekter og livskvalitet
1. Miller KM, et al. Depression symptoms in
movement disorders: comparing Parkinson’s
disease, dystonia and essensiell tremor.
Movement Disorders 2007; 22:666-72.
2. Jahanshahi M, Marsden CD. Body concept,
depression and disability in spasmodic
torticollis. Behaviour Neurol 1990; 3: 117-131.
3. Jahanshahi M, Marsden CD. A longitudinal
study of depression, disability and body
concept in torticollis. Behaviour Neurol 1990;
3: 233-246.
4. Jahanshahi M, Marsden CD. Psychological
functioning before and after treatment of
torticollis with botulinum toxin. J Neurol
Neurosurgery Psych 1992; 55: 229-231.
5. Müller J, Kemmler G, Wissel J et al. The
59
impact of blepharospasm and cervical
dystonia on health-related quality of life and
depression. J Neurol 2002; 249: 842-846.
6. Skogseid IM, Malt UF, Røislien J, Kerty E.
Determinants and status of quality of life after
long-term botulinum toxin therapy for cervical
dystonia. Eur J Neurol 2007; 14: 1129-37.
7. Gudex CM, Hawthorne MR, Butler AG, Duffey
P. Effect of Dystonia and Botulinum toxin
Treatment on Health –Related Quality of Life.
Mov Disord 1998; 13: 941-946.
8. Skogseid IM, Røislien J, Claussen B, Kerty E.
Long-term botulinum toxin treatment increases
employment rate in patients with cervical
dystonia. Mov Disord 2005; 20:1604-09.
9. Mueller J, Skogseid IM, Benecke R, et al, for
the Deep-Brain Stimulation for Dystonia Study
Group. Pallidal deep brain stimulation improves
quality of life in segmental and generalized
dystonia: Results from a prospective,
randomized sham-controlled trial. Mov Disord
2008 23 (1):131-4.
10. Beck AT, Ward CH, Mendelson M, et al (1961).
An inventory for measuring depression. Arch
Gen Psych 4: 561-571.
11. Beck AT, Epstein N, Brown G, Steer RA
(1988). An inventory for measuring clinical
anciety: Psychometric properties. J Cons Clin
Psychology Vol56(6), 893-897.
12. Zigmond AS, Snaith RP (1983). The Hospital
Anxiety and Depression Scale. Acta Psychiatr
Scand 67:361-370.
13. Ware JE, Sherbourne C (1992). The MOS 36
item short-form health survey 1: conceptual
framework and item selection. Medical Care
30: 473-483.
14. Müller J, Wissel J, Kemmler G, et al (2004).
Craniocervical dystonia questionnaire (CDQ-
24): development and validation of a diseasespecific
quality of life instrument. J Neurol
Neurosurg Psych 75: 749-753.